The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase Ⅱ clinical trial.
 
Zhong Zheng
No Relationships to Disclose
 
Yuhuan Gao
No Relationships to Disclose
 
Yongping Song
No Relationships to Disclose
 
Ying Qian
No Relationships to Disclose
 
Hongmei Jing
No Relationships to Disclose
 
Tingbo Liu
No Relationships to Disclose
 
Lei Zhang
No Relationships to Disclose
 
Xiuhua Sun
No Relationships to Disclose
 
Yang Zhang
No Relationships to Disclose
 
Li'e Lin
No Relationships to Disclose
 
Hongxia Yao
No Relationships to Disclose
 
Huilai Zhang
No Relationships to Disclose
 
Jie Jin
No Relationships to Disclose
 
Xiugao Yang
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Jing Yuan
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Xin Yan
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Wenjuan Peng
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Bin Bai
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Hengyi Zhang
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Weili Zhao
No Relationships to Disclose